Brain drain?

Biotech company employees are notorious for voting with their feet. But headhunters don't anticipate getting a flood of work as a result of Roche's decision to exercise its option to buy the rest of Genentech Inc. and then resell 19 percent on the public market.

It is generally accepted that if Roche had decided to absorb GNE, an exodus of scientists and management would have ensued. Now, some executive recruiters believe